02.09.15
A study published in the Journal of International Medical Research, found that Target 1— in a formula featuring Lactium (milk casein)— helped significantly decrease symptoms of burnout. The double-blind, randomized, placebo-controlled clinical trial looked at the effects of the formula on participants with burnout syndrome, and followed study subjects’ symptoms of burnout using different evaluation instruments for the 12-week study period.
Target 1 is a blend of casozepine (milk casein, Lactium), which is considered in the French Pharmacopoeia as having a benzodiazepine-like profile and an action that targets depressive symptoms, which are always present in burnout; Extramel, a melon extract rich in superoxide dismutase, a powerful antioxidant that reduces cellular oxidation (which is accelerated in burnout due to sleep and mood disorders, fatigue, and stress); and the amino acid taurine, which is believed to have energizing properties or anti-fatigue effects; and Eleutherococcussenticosus (Siberian ginseng), an adaptogenic herb, which is said to bolster the body's resistance to stress.
Tests included BMS-10, MBI-HSS (professional fatigue, depersonalization and task accomplishment) and Beck Depression Inventory Score.
In the placebo group, 14 participants still presented with a high level of burnout at the end of the trial compared with 26 on the first day, whereas in the supplement group, only two participants had a high level of burnout at the end of the trial compared with 33 on the first day. Study participants came from a wide range of professional backgrounds across several economic sectors.
For one measure— MBI-HSS: professional fatigue — the supplement group reported a 39.6 score at the study commencement, decreasing significantly to 16.7, while the placebo group went down slightly from 37.2 at the beginning to 33.4 at the end.
According to lead author Alain Jacquet, of the Department of Clinical Pharmacology, University of Bordeaux Segalen, Bordeaux, France, the substantial improvements in depressive symptoms (as measured by BMS-10) observed in the study may be related to the formula's inclusion of Lactium, casozepine, which is referred to as "benzodiazepine-like" in the French pharmacopoeia.
"A study by the American Institute of Stress (NY) showed that workplace stress causes more than $300 billion annually in health care, missed work and stress-reduction," says Mitch Skop, senior director of new product development for Pharmachem. "This latest study, which enhances the Lactium research portfolio, once again validates that this ingredient is a powerful tool in helping people cope with stress, and attendant feelings of anxiety, stress, sleep problems and now burnout."
For more information: www.pharmachemlabs.com
Target 1 is a blend of casozepine (milk casein, Lactium), which is considered in the French Pharmacopoeia as having a benzodiazepine-like profile and an action that targets depressive symptoms, which are always present in burnout; Extramel, a melon extract rich in superoxide dismutase, a powerful antioxidant that reduces cellular oxidation (which is accelerated in burnout due to sleep and mood disorders, fatigue, and stress); and the amino acid taurine, which is believed to have energizing properties or anti-fatigue effects; and Eleutherococcussenticosus (Siberian ginseng), an adaptogenic herb, which is said to bolster the body's resistance to stress.
Tests included BMS-10, MBI-HSS (professional fatigue, depersonalization and task accomplishment) and Beck Depression Inventory Score.
In the placebo group, 14 participants still presented with a high level of burnout at the end of the trial compared with 26 on the first day, whereas in the supplement group, only two participants had a high level of burnout at the end of the trial compared with 33 on the first day. Study participants came from a wide range of professional backgrounds across several economic sectors.
For one measure— MBI-HSS: professional fatigue — the supplement group reported a 39.6 score at the study commencement, decreasing significantly to 16.7, while the placebo group went down slightly from 37.2 at the beginning to 33.4 at the end.
According to lead author Alain Jacquet, of the Department of Clinical Pharmacology, University of Bordeaux Segalen, Bordeaux, France, the substantial improvements in depressive symptoms (as measured by BMS-10) observed in the study may be related to the formula's inclusion of Lactium, casozepine, which is referred to as "benzodiazepine-like" in the French pharmacopoeia.
"A study by the American Institute of Stress (NY) showed that workplace stress causes more than $300 billion annually in health care, missed work and stress-reduction," says Mitch Skop, senior director of new product development for Pharmachem. "This latest study, which enhances the Lactium research portfolio, once again validates that this ingredient is a powerful tool in helping people cope with stress, and attendant feelings of anxiety, stress, sleep problems and now burnout."
For more information: www.pharmachemlabs.com
